danmaku icon

Moderna 177% after initial melanoma results showed its personalized vaccine with Merc

0 Ditonton12 jam yang lalu

Moderna surged 177% after initial melanoma results showed its personalized vaccine with Merck's Keytruda outperformed Keytruda alone in recurrence-free and metastasis-free survival. The companies did not disclose the duration of that benefit or whether patients lived longer overall.
warn iconDilarang memposting ulang tanpa izin dari Kreator.
creator avatar

Direkomendasikan untukmu

  • Semua
  • Anime